About half of patients with diffuse large B-cell lymphoma (DLBCL) do not respond to or relapse soon after the standard chemotherapy, indicating a critical need to better understand the specific pathways perturbed in DLBCL for developing effective therapeutic approaches. Mice deficient in the E3 ubiquitin ligase Smurf2 spontaneously develop B-cell lymphomas that resemble human DLBCL with molecular features of germinal center or post-germinal center B cells. Here we show that Smurf2 mediates ubiquitination and degradation of YY1, a key germinal center transcription factor. Smurf2 deficiency enhances YY1-mediated transactivation of c-Myc and B-cell proliferation. Furthermore, Smurf2 expression is significantly decreased in primary human DLBCL samples, and low levels of Smurf2 expression correlate with inferior survival in DLBCL patients. The Smurf2-YY1-c-Myc regulatory axis represents a novel pathway perturbed in DLBCL that suppresses B-cell proliferation and lymphomagenesis, suggesting pharmaceutical targeting of Smurf2 as a new therapeutic paradigm for DLBCL.
Introduction
In response to antigen stimulation, B cells undergo extensive proliferation to form germinal centers (GCs) in secondary lymphoid organs 1 . As a consequence of cell proliferation, mutagenic events may occur and target cancer-causing genes. In addition, B cells in GCs undergo distinct genetic processes to generate high-affinity antibodies, including somatic hypermutation (SHM) of the variable region of the immunoglobulin gene and class switch Users may view, print, copy, download and text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms recombination (CSR) that changes immunoglobulin class. These processes can target nonimmunoglobulin genes in the GC B cells, leading to genetic alterations that promote tumorigenesis 2, 3, 4, 5, 6, 7, 8 . To counteract these oncogenic effects, it has been postulated that tumor suppressors function to constrain the proliferation and survival of GC B cells at risk of malignant transformation. Identification of these specific tumor suppressors is critical to our understanding of malignancies originated in GCs.
Most non-Hodgkin's lymphomas (NHLs) are derived from GC B cells or B cells that have passed through GCs 9, 10 . Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for 30-40% of all new diagnoses 11 . Significant progress has been made in our understanding of the dysregulated pathways and genetic abnormalities that govern the development of DLBCL 10, 12, 13 . Current chemotherapy regimens using the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), together with the anti-CD20 monoclonal antibody rituximab (R-CHOP), result in long-term remission in approximately 50% of DLBCL patients 14 . However, a significant fraction of DLBCL are still incurable, indicating that further understanding of the pathogenesis of this disease is needed in order to develop specific and effective therapeutic approaches.
Recently it has been shown that mice deficient in Smurf2 (Smad ubiquitination regulatory factor-2) spontaneously develop tumors including lymphomas of B-cell origin, indicating that Smurf2 functions as a tumor suppressor 15, 16 . It has been proposed that Smurf2 exerts its tumor suppressor function through its ability to maintain genomic integrity 15 and regulate senescence 16 . In this report, we find that B-cell lymphomas developed in Smurf2-deficient mice resemble human DLBCL with molecular features of GC or post-GC B cells. We discover that Smurf2 ubiquitinates YY1, a master regulator of GC transcriptional program 17 , through which Smurf2 suppresses cell proliferation and c-Myc expression. This Smurf2-YY1-cMyc regulatory axis provides novel insight into lymphomagenesis in GC or post-GC B cells and is highly relevant in human DLBCL.
Results

B-cell lymphoma in Smurf2-deficient mice resembles DLBCL
Previously we have shown that Smurf2-deficient (Smurf2 T/T , T for the gene-trapped Smurf2 allele) or the heterozygous Smurf2 +/T mice exhibit increased susceptibility to spontaneous tumorigenesis after 12 months of age, with the majority of tumors (72.7%) being lymphomas in spleen with a B-cell origin (i.e., B220 + ). All tumor-bearing Smurf2 T/T or Smurf2 +/T mice have enlarged spleens 16 , prompting us to characterize spleens in mice before malignancy. Compared with wild-type mice, an increase in spleen weight relative to body weight was found in 2-month old Smurf2 T/T mice ( Fig. 1a; 45.2% increase, P=0.021, Student t-test) or Smurf2 +/T mice (Supplementary Fig. S1a ; 22.5% increase, P=0.07, Student t-test). This increase in spleen weight was accompanied by an increase in total splenic cells (Fig. 1b) and B220 + B cells (Fig. 1c) , meanwhile the frequency of splenic B220 + B cells remained unchanged in young Smurf2 T/T compared to wild-type mice (Fig. 1c) . Further, we analyzed B-cell development in bone marrow and spleen using flow cytometry. Between young Smurf2 T/T and wild-type mice, we found no obvious difference in the frequencies of various B-cell sub-populations in bone marrow ( Supplementary Fig. S2 and S3) and spleen (Fig. 1d, Fig. 2 and Supplementary Fig. S4 ), suggesting that B-cell development and differentiation are normal in Smurf2-deficient mice.
In lymphoma-bearing spleens of Smurf2-deficient mice, we observed a significant expansion (average 6.3-fold increase compared to wild-type mice) of IgD neg IgM low B cells that were CD23 negative and heterogeneous for CD24 (Fig. 3a) , suggesting a GC or post-GC phenotype. This expansion of IgD neg IgM low B cells in tumor-bearing mice is in sharp contrast with young mice before malignancy, in which the frequency of the IgD neg IgM low B-cell population was similar between young Smurf2-deficient and wild-type mice (Fig. 1d) . Consistent with being GC-derived, these lymphomas showed positive staining for the GC markers peanut agglutinin (PNA) and CD95 (Fig. 3b,c) , underwent class switch recombination to immunoglobulin γ2a ( Fig. 3c and Supplementary Fig. S5 ) and exhibited increased somatic hypermutation in the immunoglobulin heavy chain (IgH) locus (Supplementary Table S1 ). Moreover, these lymphomas showed a gene expression pattern analogous to that in human DLBCL (Supplementary Fig. S6a ). Collectively, these data indicate that lymphomas developed in Smurf2-deficient mice are GC or post-GC derived and have molecular features consistent with DLBCL 18 .
We analyzed the genomic rearrangements of the IgH locus in representative lymphomabearing spleen samples, and detected a specific V(D)J rearrangement in some lymphoma samples ( Supplementary Fig. S6b ), consistent with a clonal origin of these lymphomas. The lack of detection of a rearrangement using the largest V H family (J588) in other lymphoma samples may reflect the presence of non-neoplastic cells in spleen samples, rearrangement with a different V H family, or oligoclonal origin. To further investigate tumorigenicity of Smurf2-deficient lymphomas, we injected splenic cells from lymphoma-bearing Smurf2-deficient mice into sub-lethally irradiated Rag1 knockout (Rag1 −/− ) mice. Rag1 −/− recipient mice became moribund 6-8 weeks after injection. An extensive expansion of IgD neg IgM low B cells was observed in the spleens of these Rag1 −/− recipients (Fig. 3c) (Fig. 3c) . Positive staining for IgG2a confirmed that these tumors underwent class switch recombination (Fig. 3c) . Given that the expanded population of IgD neg IgM low B cells in Rag1 −/− mice had the same GC B-cell phenotype as the injected tumor cells, and that the recipient Rag1 −/− mice became moribund, these data are consistent with transfer of disease resembling DLBCL.
Enhanced proliferation in Smurf2-deficient splenic B cells
Lymphomas found in Smurf2-deficient mice showed an increase in the frequency of cells positive for the cell proliferation-associated antigen Ki-67 compared to spleen sections of age-matched wild-type mice (Fig. 4a) . Interestingly, Ki-67 staining was increased in spleen, particularly white pulp, of 2-month old Smurf2 T/T (Fig. 4b, c) or Smurf2 +/T mice ( Supplementary Fig. S1b ) compared to wild-type littermates. Furthermore, increased bromodeoxyuridine (BrdU) incorporation was detected in B220 + splenic B cells (Fig. 4d) or total splenic cells ( Supplementary Fig. S7a ) of young Smurf2 T/T mice compared to wild-type littermates. Taken together, these results suggest that increased cell proliferation observed in Smurf2-deficient splenic B cells and B-cell lymphomas is caused by reduced Smurf2 expression rather than as a consequence of tumorigenesis.
To further analyze cell proliferation in splenic B cells, we cultured total spleen cells of 2-month old wild-type or Smurf2 T/T mice with the B-cell mitogen lipopolysaccharide (LPS). In response to LPS, Smurf2 T/T splenic B220 + B cells proliferated significantly better than wildtype cells (Fig. 4e) , whereas cell viability was similar between them ( Supplementary Fig.  S7b ). Using carboxyfluorescein succinimidyl ester (CFSE) to track cell divisions in cultured splenic B cells, we found that the number of Smurf2 T/T splenic B cells undergoing successive cell divisions was significantly increased compared to wild-type cells ( Fig. 4f and Supplementary Fig. S7c ). Without LPS stimulation, cell death was similar between wildtype and Smurf2 T/T B cells ( Fig. 4e and Supplementary Fig. S7b ). Furthermore, TUNEL staining for apoptosis was similar when spleen sections from 2-month old Smurf2 T/T mice or lymphomas were compared to age-matched wild-type mice (Fig. 4a, b ). Both observations suggest that apoptosis is unchanged in Smurf2-deficient cells. Collectively, these results indicate that cell proliferation is enhanced in Smurf2 T/T splenic B cells, suggesting a possible mechanism underlying increased B-cell lymphomagenesis in Smurf2-deficient mice.
Elevated c-Myc expression in Smurf2-deficient mice
As up-regulation of c-Myc is frequently observed in B-cell lymphoma, and forced expression of c-Myc drives lymphomagenesis in mice 19, 20, 21 , it prompted us to examine cMyc expression in lymphomas derived from Smurf2 T/T or Smurf2 +/T mice. The expression of c-Myc mRNA in these lymphomas was increased compared with spleens of wild-type mice of the similar age (Fig. 5a ), while no IgH-Myc translocation was detected in lymphomas in Smurf2-deficient mice ( Supplementary Fig. S8 ).
To understand whether c-Myc elevation underlies increased B-cell proliferation and lymphomagenesis in Smurf2-deficient mice, we examined c-Myc expression in young Smurf2 T/T mice at the pre-neoplastic stage. We found an increase in c-Myc expression in spleen (Fig. 5b ) and liver ( Supplementary Fig. S9a, b ) of 2-month old Smurf2 T/T mice compared with age-matched wild-type mice, suggesting that Smurf2 deficiency leads to increased c-Myc expression. To further corroborate c-Myc mRNA elevation with Smurf2 deficiency, we examined the transcript levels of c-Myc transactivation targets Apex1, Cad and Ncl, which have been validated as c-Myc targets in multiple studies, but are not directly involved in cell proliferation (http://www.myccancergene.org/site/mycTargetDB.asp) 22 . We found increased transcript levels of these c-Myc targets in lymphomas (Fig. 5c ) as well as spleen ( Fig. 5d) and liver of young Smurf2 T/T mice ( Supplementary Fig. S9c ).
Smurf2 ubiquitinates YY1 to regulate c-Myc expression
To investigate the underlying mechanism of Smurf2-mediated regulation of c-Myc expression, we searched for transcriptional regulators that have been shown to transactivate c-Myc and examined their potential as the ubiquitination targets of Smurf2. We reasoned that stabilization of such a transcriptional regulator in Smurf2-deficient mice could be responsible for elevated expression of c-Myc. YY1, which transactivates c-Myc 23, 24 and is a central regulator of the GC B-cell-specific transcriptional program 17 , contains a PPDY motif that can potentially interact with the WW domains in Smurf2. We found that the protein levels of YY1 were increased in lymphomas derived from Smurf2 T/T or Smurf2 +/T mice ( Fig. 6a ) as well as in spleen (Fig. 6b ) and liver ( Supplementary Fig. S9b ) of young Smurf2 T/T mice compared with wild-type littermates. In contrast, the transcript level of YY1 was largely unchanged in Smurf2-deficient mice (Fig. 6b) , suggesting a post-transcriptional regulation of YY1 by Smurf2. Supporting this notion, the protein half-life of YY1 was increased from 2.1-hr in wild-type splenic B cells to 4.4-hr in splenic B cells of Smurf2 T/T mice ( Fig. 6c) , suggesting that Smurf2 deficiency leads to an increase in protein stability of YY1.
To further characterize Smurf2-mediated regulation of YY1, we stably expressed shorthairpin RNA (shRNA) targeting Smurf2 in a human DLBCL cell line (SUDHL-6), and found that down-regulation of Smurf2 led to an increase in YY1 protein (Fig. 7a) . Conversely, ectopic expression of Smurf2 resulted in a reduction in the steady-state level of YY1 protein. In contrast, a ligase mutant C716A, in which the conserved cysteine at residue 716 is replaced by alanine to abolish its E3 ubiquitin ligase activity 25, 26, 27 , did not lead to changes in YY1 (Fig. 7b ), indicating that regulation of YY1 bySmurf2 requires its ubiquitin ligase activity. Consistent with what we found in Smurf2-deficient mice ( Fig. 5 ), c-Myc transcripts were regulated by Smurf2 (Fig. 7a, b ). In contrast, YY1 transcripts were largely unchanged when Smurf2 expression was altered (Fig. 7a, b) , consistent with the notion that Smurf2 regulates YY1 post-transcriptionally. These results led us to hypothesize that Smurf2 is the E3 ubiquitin ligase responsible for ubiquitination of YY1.
To test this hypothesis, we first investigated whether Smurf2 interacts with YY1, as the C2-WW-HECT class of E3 ligases interacts with their protein substrates to catalyze ubiquitination. To limit potential degradation of YY1 by Smurf2, we used the ligase mutant C716A in co-immunoprecipitation with YY1. Smurf2 and YY1 were found to form a complex by co-immunoprecipitation, whereas deletion of the PPDY motif of YY1 (ΔPY) abolished the Smurf2-YY1 interaction (Fig. 7c) . Furthermore, we found that three WW domains (i.e. WWs), but not the C2 or HECT domain of Smurf2 alone, were sufficient to interact with YY1. Deletion of the N-terminal WW domain (ΔWW1) abolished the interaction between Smurf2 and YY1 (Fig. 7c) . Collectively, these results indicate that the Smurf2-YY1 interaction is mediated by the WW domains of Smurf2 and the PPDY motif of YY1.
We next investigated whether Smurf2 induces ubiquitination of YY1. Ubiquitination of YY1 was greatly induced in the presence of Smurf2 compared with a GFP control, whereas catalytically inactive C716A lost the ability to ubiquitinate YY1 ( Fig. 7d and Supplementary  Fig. S10 ). Furthermore, deletion of the PPDY motif in YY1 diminished Smurf2-mediated ubiquitination ( Fig. 7d and Supplementary Fig. S10 ). Conversely, we used stably expressed shRNA to knockdown the expression of Smurf2 in SUDHL-6 cells, and found that downregulation of Smurf2 resulted in decreased ubiquitination of endogenous YY1 (Fig. 7e) . Collectively, these results indicate that Smurf2 is the E3 ubiquitin ligase responsible for ubiquitination of YY1.
YY1 has been shown to bind to the human c-Myc promoter in a chromatin immunoprecipitation (ChIP) assay and to be sufficient to up-regulate c-Myc expression 23, 24 . We expressed shRNA to knockdown YY1 expression in SUDHL-6 cells, and found that cMyc transcripts were decreased upon YY1 down-regulation (Fig. 8a ), indicating that YY1 is required to regulate c-Myc expression. As shRNA knockdown of Smurf2 expression in SUDHL-6 cells led to elevation of c-Myc, further down-regulation of YY1 by shRNA resulted in decreased c-Myc expression (Fig. 8b) , suggesting that YY1 is the critical mediator of Smurf2-regulated c-Myc expression. Further supporting this notion, knockdown of YY1 expression by siRNA led to down-regulation of c-Myc in primary B cells isolated from spleens of wild-type and Smurf2 T/T mice (Fig. 8c) . Moreover, ChIP analysis indicated that YY1 was bound to the c-Myc promoter in mouse spleen, and this binding was increased in spleen of Smurf2 T/T mice compared with wild-type mice (Fig. 8d) , consistent with the mechanism in which stabilization of YY1 in Smurf2-deficient cells up-regulates c-Myc expression.
Smurf2 and YY1 regulate proliferation of DLBCL cells
To understand the consequence of Smurf2-mediated ubiquitination of YY1 in lymphomagenesis, we investigated the Smurf2-YY1 axis in regulation of cell proliferation in human DLBCL cells. Consistent with our observation of increased cell proliferation in Smurf2-deficient mice, shRNA knockdown of Smurf2 expression inSUDHL-6 cells (Fig.  8b ) led to enhanced cell proliferation (Fig. 8e) . Down-regulation of YY1 by shRNA (Fig. 8b ) resulted in decreased proliferation in SUDHL-6 cells, indicating that YY1 is a critical regulator of cell proliferation in DLBCL cells (Fig. 8e) . Furthermore, down-regulation of YY1 in SUDHL-6 cells that already had shRNA knockdown of Smurf2 (Fig. 8b) alleviated the increase in cell proliferation mediated by Smurf2 deficiency (Fig. 8e) , suggesting that Smurf2 regulates cell proliferation through YY1. Conversely, ectopic expression of wildtype Smurf2, but not the ligase mutant C716A, in SUDHL-6 cells (Fig. 7b) led to significantly decreased cell proliferation (Fig. 8f) , while apoptosis was not significantly changed (Fig. 8g) . Taken together, these results indicate the Smurf2-YY1 regulatory axis is critical in proliferation of lymphoma cells, providing a plausible mechanism underlying increased cell proliferation and lymphomagenesis in Smurf2-deficient mice.
Smurf2 expression correlates with DLBCL patient survival
To investigate whether Smurf2 deficiency has clinical relevance in human lymphomagenesis, we analyzed Smurf2 expression in primary human lymphoma samples. In a published microarray dataset (GSE2350) that contains samples of human primary B-cell lymphoma and normal B cells 28 , we found that the expression of Smurf2 was significantly decreased in DLBCL, Burkitt's lymphoma and follicular lymphoma compared to normal B cells (Fig. 9a) .
To further understand the relevance of decreased Smurf2 expression in human lymphomagenesis, we next investigated whether the level of Smurf2 expression correlates with clinical outcome. Smurf2 expression has been measured in three human primary B-cell lymphoma microarray datasets, each of which contains survival information of more than 100 patients 29, 30, 31 . Within each dataset, we divided lymphoma samples into four groups based on the level of Smurf2 expression, with the 1 st quartile having the lowest Smurf2 expression. Survival analysis of dataset GSE4475 in Gene Expression Omnibus (GEO, http://www.ncbi.nil.nih.gov/geo), which contains DLBCL and some Burkitt's lymphoma patients 29 , showed that overall survival of patients with the lowest Smurf2 expression (1 st quartile) was significantly worse (P<0.0001, log-rank test) than that of patients with higher Smurf2 expression (2 nd -4 th quartile) (Fig. 9b) . Similarly, a significantly poor survival prognosis (P=0.0004, log-rank test) was observed in patients with low level of Smurf2 expression (1 st and 2 nd quartiles) compared to patients with high level of Smurf2 expression (3 rd and 4 th quartiles) in an independent dataset GSE10846 in GEO (Fig. 9c) , which contains only DLBCL patients 30 . Interestingly, we found no significant difference in overall survival of patients in a human follicular lymphoma dataset 31 based on Smurf2 expression level (Fig.  9d) , suggesting a specific role of Smurf2 deficiency in human DLBCL or possibly Burkitt's lymphoma.
Certain clinical and molecular parameters have been shown to predict DLBCL patient survival 32, 33, 34 . Univariate analysis indicated a significant correlation between poor survival prognosis and age, Ann Arbor stage, molecular subtype, or International Prognostic Index (IPI) score. To determine whether Smurf2 expression can predict clinical outcomes independently of these known parameters, we carried out a multivariate Cox regression analysis, and found that low level of Smurf2 expression was an independent predictor of patient survival in both DLBCL cohorts (P=0.01 for GSE4475 and P=0.027 for GSE10846) ( Table 1 ). These results indicate that Smurf2 expression is a valuable prognostic marker for DLBCL patient survival, and further suggest that Smurf2 is a potential therapeutic target for DLBCL.
Discussion
In this study, we found that lymphomas developed in Smurf2-deficient mice have molecular features of GC or post-GC B cells and resemble human DLBCL. A significant decrease in Smurf2 expression is found in human DLBCL compared to normal B cells, indicating the clinical relevance of Smurf2 deficiency in human lymphomagenesis. Furthermore, our finding that low levels of Smurf2 expression correlate with poor survival prognosis in DLBCL patients suggests that Smurf2 is part of an important molecular pathway controlling lymphoma development. This pathway, identified in this study as the Smurf2-YY1-c-Myc regulatory axis, is novel and specific in suppression of B-cell proliferation and consequently lymphomagenesis. To our knowledge, Smurf2 is the first E3 ligase identified to ubiquitinate YY1. As a transcriptional regulator, YY1 plays a critical role in many biological processes including development, differentiation and proliferation, and has been implicated in oncogenesis 35, 36 . Specific to B cells, YY1 is a critical regulator of B-cell development 37 , and has recently been identified as a central regulator of the GC B-cell-specific transcriptional program 17 . The expression of YY1 is found to be increased in high-grade DLBCL or Burkitt's lymphoma compared to low grade lymphoma or normal B cells 38 . Furthermore, elevated YY1 expression correlates with poor survival prognosis of DLBCL patients 39 , suggesting an oncogenic function for YY1 in human B-cell lymphomagenesis. The Smurf2-YY1-c-Myc regulatory axis is thus a useful prognostic predictor of clinical outcome in DLBCL patients and a potential therapeutic target for treatment of DLBCL.
There is no evidence that the Smurf2 locus is deleted in human DLBCL 40, 41 or Burkitt's lymphoma 42, 43 , suggesting that epigenetic regulation probably plays an important role in Smurf2 deficiency in human lymphomagenesis. Moreover, we showed that restoration of Smurf2 expression in human DLBCL cells can suppress cell proliferation (Fig. 8f) , providing an opportunity to design strategies to increase the expression of Smurf2 in lymphomas as a new therapeutic approach complementing current CHOP/R-CHOP regimens.
Increased susceptibility to B-cell lymphomagenesis in Smurf2-deficient mice is preceded by enhanced proliferation in splenic B cells. B cells undergo SHM and CSR in GCs to generate high-affinity antibodies. Both SHM and CSR are mutagenic and may target nonimmunoglobulin genes. These "off-target" genetic alterations contribute to lymphomagenesis 2, 3, 4, 5, 6, 7, 8 . Enhanced proliferation would predispose Smurf2-deficient B cells to these mutagenic events, which ultimately contribute to lymphomagenesis. Consistent with this notion, Smurf2-deficient mice develop lymphomas at 12-15 months of age, most likely reflecting the infrequent generation of splenic GCs in un-immunized mice along with the accumulation of mutations with age. Recently it has been shown that Smurf2 regulates histone H2B monoubiquitination by targeting ring finger protein 20 (RNF20) for ubiquitination and degradation. Loss of Smurf2 leads to genomic instability through alterations in histone modification 15 , suggesting an important mechanism through which Smurf2 functions as a tumor suppressor. Our work now adds a novel dimension to the tumor suppressive functions of Smurf2.
As YY1 has been shown to transactivate c-Myc expression 23, 24 , our discovery of Smurf2-mediated ubiquitination and degradation of YY1 provides a novel mechanism by which Smurf2 regulates c-Myc expression and cell proliferation. Myc translocation is not common in DLBCL (5-10%), however, increased Myc expression is observed in ~30% of DLBCL and correlates with poor survival prognosis in DLBCL patients 44 . While no IgH-Myc translocation was found, lymphomas derived from Smurf2-deficient mice all showed increased expression of c-Myc. The Smurf2-YY1-c-Myc axis identified in the present study provides a plausible mechanism for increased Myc expression without chromosomal translocation in DLBCL.
As a master regulator of cell proliferation 45 , the oncogenic function of c-Myc in B-cell lymphomagenesis is well documented 19, 20, 21, 46 . In response to activated oncogenes, intrinsic tumor suppression mechanisms such as apoptosis and senescence are triggered to restrain oncogenic proliferation. With c-Myc, an additional layer of complexity is provided by the exquisite sensitivity of cells to different levels of c-Myc overexpression. High level of c-Myc overexpression increases cell proliferation and drives lymphomagenesis, but also induces apoptosis 20, 21, 47 . Suppression of apoptosis exacerbates c-Myc-induced lymphomagenesis, suggesting that apoptosis antagonizes c-Myc's oncogenic activity 21 . Further, it has been recently found that low level of c-Myc elevation promotes cell proliferation without inducing apoptosis 48 . Consistent with this observation, we found that Smurf2-deficient mice showed low level (~2-fold) of c-Myc elevation (Fig. 5b) and enhanced proliferation in B cells without significant induction of apoptosis (Fig. 4 and Supplementary Fig. S7 ). In the absence of apoptosis, senescence likely becomes the critical tumor suppression mechanism to antagonize the oncogenic activity of Myc. A recent study shows that constitutive activation of c-Myc indeed activates senescence 49 . Smurf2 is an important regulator of senescence 16, 50, 51, 52 . In Smurf2-deficient cells, impaired senescence response leads to prolonged cell proliferation including in splenic cells 16 , suggesting that enhanced cell proliferation induced by low level of c-Myc activation coupled with an impaired senescence response drives lymphomagenesis in Smurf2-deficient mice. Smurf2 thus plays multiple roles in tumor suppression by maintaining chromatin landscape and genomic stability, suppressing cell proliferation and regulating the senescence response.
Methods
Smurf2-deficient mice
Smurf2-deficient mice as described previously 16 have been backcrossed to C57BL/6 for >10 generations. Tissues were harvested for DNA, RNA and protein preparation, or fixed in 10% phosphate-buffered formalin. 5-μm paraffin sections were stained for Hematoxylin & Eosin, PNA (Vector Labs), TUNEL (Roche), B220 and Ki-67 (antibody sources and dilutions in Supplementary Table S2 ). For transplantation, 2×10 6 splenic cells from tumor-bearing mice were injected retro-orbitally into sub-lethally irradiated (3 Gy) Rag1 −/− mice (Jackson Laboratories). All studies were carried out according to guidelines approved by the Institutional Animal Care and Use Committee of University of Massachusetts Medical School.
Flow cytometry
Spleens were collected from 2-month old mice of both sexes and ground between frosted glass slides. Bone marrow cells were harvested from long leg bones. After red blood cells were lysed, cells were filtered through 70-μm nylon mesh and incubated with anti-CD16/32 antibody (10 min on ice). Cells were incubated with primary antibodies for 20 min and washed three times with staining media (biotin-, flavin-, and phenol red-deficient RPMI-1640 medium with 10 mM pH7.2 HEPES, 0.02% sodium azide, 1 mM EDTA and 2% FBS). Antibodies (sources and dilutions in Supplementary Table S3 ) included B220-APC (RA3-6B2), CD19-PE-TR (ID3), CD21-FITC (7G6), CD23-biotin (B3B4), CD24-FITC (30-F1), CD43-PE (S7), CD93-PE-Cy7 (AA4.1), CD95-PE (15A7), CD117(c-kit)-PECy5.5 (2B8), CD127-PE (A7R34), IgD-PE or -biotin (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , IgM-APC, -biotin or -PE-Cy7 (II/41), IgG2a-PE (m2a-15F8) and Ly6C-FITC (AL21). Biotin-stained cells were incubated with streptavidin-pacific blue (Invitrogen) for 15 min on ice, washed three times and resuspended in 1 μg/ml propidium iodide to exclude dead cells. Flow cytometry was performed on 5-laser, 18-detector LSR II (BD Biosciences), and data were analyzed using FlowJo (Treestar).
Splenic B-cell proliferation assays
Mouse spleen was collected and processed as described above. Single splenic cell suspension was treated with 10 μM carboxyfluorescein succinimidyl ester (Invitrogen) for 10 min at 37°C, and cultured in RPMI-1640 medium with 10% FBS, 100 μM MEM nonessential amino acids, 2 mM glutamine, and 50 μM 2-mercaptoethanol (Invitrogen)in a humidified chamber containing 5% CO 2 at 37°C. Cells were treated with 5 μM lipopolysaccharide (Sigma) or left untreated. Cells were stained with anti-B220-APC antibody daily for 4 days. After being washed and re-suspended in 1 μg/ml propidium iodide, cells were analyzed by flow cytometry with BD FACSCaliber and FlowJo.
Mice were injected with 1 mg bromodeoxyuridine (BrdU, BD Biosciences) intraperitoneally. Spleen was collected 24 hours later and processed as described above. Splenic cells were fixed, and stained with anti-BrdU-FITC antibody using BrdU flow kit (BD Biosciences) and anti-B220-APC antibody. Data were collected by flow cytometry on BD FACSCaliber and analyzed using FlowJo.
Cycloheximde treatment
Mouse splenic cells were harvested and cultured as described above. Cells were treated with 15 μg/ml cycloheximide (Sigma), and cell lysates were collected every 2 hours post treatment.
Class switch recombination and somatic hypermutation assays
Transcripts of mouse IgH were amplified by quantitative RT-PCR as described 53 . Briefly, μ (IgM) transcripts were amplified using primers ImF and CmR. Post-switch transcripts were amplified using the following primers: ImF and Cg1R for γ1 (IgG1), ImF and Cg2aR for γ2a (IgG2a), ImF and Cg2bR for γ2b (IgG2b), ImF and Cg3R for γ3 (IgG3). Primers used are ImF: 5′-CTCTGGCCCTGCTTATTGTTG-3′; CmR: 5′-GAAGACATTTGGGAAGGACTGACT-3′; Cg1R: 5′-GGATCCAGAGTTCCAGGTCACT-3′; Cg2aR: 5′-GCCACATTGCAGGTGATGGA-3′; Cg2bR: 5′-CACTGAGCTGCTCATAGTGTAGAGTC-3′; and Cg3R: 5′-CTCAGGGAAGTAGCCTTTGACA-3′.
The frequency of somatic mutation in mouse IgH was determined as described 53 . Briefly, V H 186.2 transcripts of mouse IgH μ isotype were amplified in RT-PCR using Phusion hot start high-fidelity Taq Polymerase (New England Biolabs) with primers V H 186.2 (5′-TTCTTGGCAGCAACAGCTACA-3′) and CmR (5′-GAAGACATTTGGGAAGGACTGACT-3′). PCR products were cloned into pGEM-T-easy vector (Promega), and individual colonies were sequenced.
Clonal analysis of mouse B-cell lymphomas
Rearrangements of the variable region of mouse IgH were analyzed as described 54 . Briefly, genomic DNA was prepared from lymphoma-bearing spleen of Smurf2-deficient mice or spleen of wild-type mice using classic genomic DNA isolation kit (LamdaBiotech), and used in PCR with primers V H (J558FR3: 5′-CAGCCTGACATCTGAGGACTCTGC-3′) and 3′ of J H4 (JH4int: 5′-CTCCACCAGACCTCTCTAGACAGC-3′).
Analysis of IgH-Myc translocation
IgH-Myc translocation in mouse B-cell lymphomas was detected as described 55 . Briefly, genomic DNA isolated from lymphomas was used as template in nested PCR using expended long PCR system (Roche). Primers were: 5′-TGAGGACCAGAGAGGGATAAAAGAGAA-3′ and 5′-GGGGAGGGGGTGTCAAATAATAAGA-3′ (1st round); 5′-CACCCTGCTATTTCCTTGTTGCTAC-3′and 5′-GACACCTCCCTTCTACACTCTAAACCG-3′ (2nd round). Myc locus was amplified as controls with primers of 5′-GGGGAGGGGGTGTCAAATAATAAGA-3′ and 5′-GTGAAAACCGACTGTGGCCCTGGAA-3′. Two lymphoma samples (318 and 334) with IgH-Myc translocation 56 were kindly provided by Dr. John Manis (Harvard Medical School) and used as positive controls.
Cell culture and transfection
SUDHL-6 cells (kindly provided by Dr. Subbarao Bondada, University of Kentucky) werecultured in RPMI-1640 medium with 10% FBS in a humidified chamber containing 5%CO 2 at 37°C. Lentiviral vectors pLenti-CMV-Smurf2-IRES-Puro, pLenti-CMV-C716A-IRES-Puro or pLenti-CMV-GFP-IRES-Puro were described previously 51 . Briefly, fragments of Smurf2 or GFP cDNA were inserted ito a lentiviral vector to express Smurf2 or GFP under the control of a CMV promoter. Lentiviral shRNA constructs targeting Smurf2 (V2LHS_10399), YY1 (V2LHS_219592, V2LHS_389741) and a non-silencing shRNA control (RHS4346) were purchased from Open Biosystems. Lentiviral packaging and infection were carried out as described 51 . Briefly, Lentiviral vectors were co-transfected with a plasmid (pMD2. VSV-G) encoding vesicular stomatitis virus glycoprotein (VSV-G) and a plasmid (pCMVdR8.74) encoding packaging proteins into 293T cells. VSV-G pseudotyped virus were collected 48 hr after transfection and used to infected target cells in the presence of 4 μg/ml polybrene (Sigma). Cells were FACS sorted for GFP+ cells (shRNA knockdown) or selected with puromycin (1 μg/ml, Sigma) for 1 week.
To analyze cell proliferation, sorted or selected cells were seeded at 5×10 3 per well in 6-well plates, harvested in triplicate and counted daily for 5 days using Z1Coulter Particle Counter (Beckman Coulter). Apoptosis was measured using Caspase-Glo 3/7 assay (Promega).
Splenic B cells were isolated using anti-B220-biotin antibody and anti-biotin beads with AutoMACS Pro (Miltenyi Biotec) and cultured with 5 μM LPS as described above. 3×10 6 cells were transfected with 10 pmol YY1 siRNA (sc-36864) or control siRNA (sc-37007, Santa Cruz Biotechnology) using mouse B cell Nucleofector kit on Nucelofector I device (Lonza) with program Z-01. Cell lysates were collected 48 hours after transfection.
Quantitative RT-PCR
Total RNA was isolated using RNeasy Mini kit (Qiagen) and reverse-transcribed using Superscript II (Invitrogen). Real-time PCR was performed using SYBR Green PCR kit (BioRad). The following primers were used: Smurf2 (F: 5′-ATGAAGTCATTCCCCAGCAC-3′; R: 5′-AACCGTGCTCGTCTCTCTTC-3′), c-Myc (F: 5′-GGACAGTGTTCTCTGCC-3′; R: 5′-CGTCGCAGATGAAATAGG-3′), YY1 (F: 5′-TGAGAAAGCATCTGCACACC-3′; R: 5′-CGCAAATTGAAGTCCAGTGA-3′), Apex1 (F: 5′-GCTCCGTCAGACAAAGAAGG-3′; R: 5′-GCATTGGGAACATAGGCTGT-3′), Cad (F: 5′-TGGTCAGTTCATCCTCACTCC-3′; R: 5′-TACATGCCGTTCTCAGCTTG-3′), Ncl (F: 5′-TAAGGGTGAAGGTGGCTTTG-3′; R: 5′-CCTTGTGGCTTGAAGTCTCC-3′) and β-actin (F: 5′-GCTCTTTTCCAGCCTTCCTT-3′; R: 5′-GTGCTAGGAGCCAGAGCAGT-3′).
Western blot and co-immunoprecipitation analysis
Total cell lysates were collected using RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mMNaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 0.02% sodium azide) with freshly added complete protease inhibitors (Roche). Protein lysates (20 μg) were separated by SDS-PAGE Criterion X-gel (Bio-Rad) and transferred to nitrocellulose membranes (GE Osmonics). Immunoblots were analyzed by Western blotting and visualized using a Western lightening chemiluminescence detection kit (PerkinElmer). Primary antibodies were Smurf2, c-Myc, YY1, Flag, HA, ubiquitin, β-actin and GAPDH (antibody sources and dilutions in Supplementary Table S2 ). For co-immunoprecipitation, cells were lysed in NP40 lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 2 nM EDTA, 1% Nonidet P-40) plus complete protease inhibitors (Roche). Lysates were incubated with anti-Flag M2 affinity gel (Sigma) overnight at 4°C. Immunoprecipitates were washed four times with NP40 lysis buffer, and analyzed in Western blot with anti-HA antibody.
Ubiquitination assay
293T cells were transfected with HA-YY1 (a gift of Dr. Yang Shi, Harvard Medical School), 3xFlag-ubiquitin (provided by Dr. Quan Lu, Harvard School of Public Health) and Smurf2. GFP and C716A were used as controls. Cells were treated with MG132 (20 μM, Sigma) for 2 hours and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 0.02% sodium azide) plus 10 mM Nethylmaleimide (Fisher Scientific). Cell lysates were incubated with anti-HA or anti-Flag affinity gel (Sigma) overnight at 4°C. Immunoprecipitates were washed with RIPA buffer three times, and analyzed in Western blot with anti-Flag or anti-HA antibody to detect ubiquitin conjugation. To detect ubiquitination of endogenous YY1 in SUDHL-6 cells, cell lysates were incubated with anti-YY1 antibody overnight at 4°C followed by incubation with protein A-agarose (Invitrogen). Poly-ubiquitinated YY1 was detected in Western blot using anti-ubiquitin antibody.
Chromatin immunoprecipitation assay
Mouse spleen was collected and processed as described above. Single cell suspension was cross-linked using 1% formaldehyde (Sigma) in RPMI-1640 medium (room temperature for 10 min). After neutralization with glycine (125 nM), cells were lysed in SDS lysis buffer. Chromatin was sonicated to fragments of ~500 bp, and Chromatin immunoprecipitation (ChIP) with anti-YY1 antibody or matched IgG was performed using ChromaFlash one step ChIP kit (Epigentek). After reverse of cross-linking (65°C for 3 hours), the c-Myc promoter region containing the YY1 binding site was amplified in quantitative PCR with primers: F: 5′-TCCCCAGCCTTAGAGAGACG-3′ and R: 5′-GGCTCCGGGGTGTAAACAGT-3′. Chromatin before ChIP was used as input.
Gene expression and statistical analyses
Microarray data (GSE2350, GSE4475 and GSE10846) were retrieved from GEO(http:// www.ncbi.nil.nih.gov/geo). Expression of Smurf2 (log 2 transformed) was analyzedwith dot plot, and one-way ANOVA was used for statistical analysis. Kaplan-Meier survival curves were plotted using GraphPad Prism 5.0, and log-rank test was used for statistical analysis.
Univariate and multivariate Cox regression analyses were used to estimate the hazard ratios and 95% confidence intervals, and statistical significance was analyzed using SPSS Statistics 19 software (IBM).
Human DLBCL dataset GSE10846 contains samples from patients receiving CHOP or R-CHOP treatment. Revised International Prognostic Index (IPI) score was used to group these patients: low (0), intermediate (1 or 2) or high (3, 4 or 5) 34 . Some IPI variables were missing in some samples. If the missing IPI variables did not change the IPI grouping of a given sample, this sample was included in the analysis. Otherwise, the sample was excluded.
Data were presented as mean ± SD. Two-tailed and unpaired Student t-test was used for pairwise comparisons, with P<0.05 considered as statistically significant.
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